Chiasma
Needham
About Chiasma
Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company's Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver. It is applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $371.0M
- Funding stage: M&A
- Last round: Post-IPO Equity (Jul 2020)
- Ticker: nasdaq:CHMA
- Website: chiasma.com
- Phone: +1 844 304 2462
Industries & Categories
Biopharma, Biotechnology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/chiasma-218345 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.